191 related articles for article (PubMed ID: 36087611)
1. Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Vlaar APJ; Witzenrath M; van Paassen P; Heunks LMA; Mourvillier B; de Bruin S; Lim EHT; Brouwer MC; Tuinman PR; Saraiva JFK; Marx G; Lobo SM; Boldo R; Simon-Campos JA; Cornet AD; Grebenyuk A; Engelbrecht JM; Mukansi M; Jorens PG; Zerbib R; Rückinger S; Pilz K; Guo R; van de Beek D; Riedemann NC;
Lancet Respir Med; 2022 Dec; 10(12):1137-1146. PubMed ID: 36087611
[TBL] [Abstract][Full Text] [Related]
2. Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial.
Vlaar APJ; de Bruin S; Busch M; Timmermans SAMEG; van Zeggeren IE; Koning R; Ter Horst L; Bulle EB; van Baarle FEHP; van de Poll MCG; Kemper EM; van der Horst ICC; Schultz MJ; Horn J; Paulus F; Bos LD; Wiersinga WJ; Witzenrath M; Rueckinger S; Pilz K; Brouwer MC; Guo RF; Heunks L; van Paassen P; Riedemann NC; van de Beek D
Lancet Rheumatol; 2020 Dec; 2(12):e764-e773. PubMed ID: 33015643
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic analysis of vilobelimab, anaphylatoxin C5a and antidrug antibodies in PANAMO: a phase 3 study in critically ill, invasively mechanically ventilated COVID-19 patients.
Lim EHT; Vlaar APJ; de Bruin S; Rückinger S; Thielert C; Habel M; Guo R; Burnett BP; Dickinson J; Brouwer MC; Riedemann NC; van de Beek D;
Intensive Care Med Exp; 2023 Jun; 11(1):37. PubMed ID: 37332066
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
5. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial.
François B; Jafri HS; Chastre J; Sánchez-García M; Eggimann P; Dequin PF; Huberlant V; Viña Soria L; Boulain T; Bretonnière C; Pugin J; Trenado J; Hernandez Padilla AC; Ali O; Shoemaker K; Ren P; Coenjaerts FE; Ruzin A; Barraud O; Timbermont L; Lammens C; Pierre V; Wu Y; Vignaud J; Colbert S; Bellamy T; Esser MT; Dubovsky F; Bonten MJ; Goossens H; Laterre PF;
Lancet Infect Dis; 2021 Sep; 21(9):1313-1323. PubMed ID: 33894131
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial.
Ely EW; Ramanan AV; Kartman CE; de Bono S; Liao R; Piruzeli MLB; Goldman JD; Saraiva JFK; Chakladar S; Marconi VC;
Lancet Respir Med; 2022 Apr; 10(4):327-336. PubMed ID: 35123660
[TBL] [Abstract][Full Text] [Related]
8. A randomised, double-blind, placebo-controlled, pilot trial of intravenous plasma purified alpha-1 antitrypsin for SARS-CoV-2-induced Acute Respiratory Distress Syndrome: a structured summary of a study protocol for a randomised, controlled trial.
McEvoy NL; Clarke JL; Mc Elvaney OJ; Mc Elvaney OF; Boland F; Hyland D; Geoghegan P; Donnelly K; Friel O; Cullen A; Collins AM; Fraughen D; Martin-Loeches I; Hennessy M; Laffey JG; Mc Elvaney NG; Curley GF
Trials; 2021 Apr; 22(1):288. PubMed ID: 33874981
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of inhaled IBIO123 for mild-to-moderate COVID-19: a randomised, double-blind, dose-ascending, placebo-controlled, phase 1/2 trial.
Maranda B; Labbé SM; Lurquin M; Brabant P; Fugère A; Larrivée JF; Grbic D; Leroux A; Leduc F; Finzi A; Gaudreau S; Swart Y;
Lancet Infect Dis; 2024 Jan; 24(1):25-35. PubMed ID: 37619584
[TBL] [Abstract][Full Text] [Related]
10. Intravenous ravulizumab in mechanically ventilated patients hospitalised with severe COVID-19: a phase 3, multicentre, open-label, randomised controlled trial.
Annane D; Pittock SJ; Kulkarni HS; Pickering BW; Khoshnevis MR; Siegel JL; Powell CA; Castro P; Fujii T; Dunn D; Smith K; Mitter S; Kazani S; Kulasekararaj A
Lancet Respir Med; 2023 Dec; 11(12):1051-1063. PubMed ID: 36958364
[TBL] [Abstract][Full Text] [Related]
11. Effect of dexamethasone in patients with ARDS and COVID-19 - prospective, multi-centre, open-label, parallel-group, randomised controlled trial (REMED trial): A structured summary of a study protocol for a randomised controlled trial.
Maláska J; Stašek J; Duška F; Balík M; Máca J; Hruda J; Vymazal T; Klementová O; Zatloukal J; Gabrhelík T; Novotný P; Demlová R; Kubátová J; Vinklerová J; Svobodník A; Kratochvíl M; Klučka J; Gál R; Singer M;
Trials; 2021 Mar; 22(1):172. PubMed ID: 33648568
[TBL] [Abstract][Full Text] [Related]
12. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA
Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777
[TBL] [Abstract][Full Text] [Related]
13. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
Rilinger J; Kern WV; Duerschmied D; Supady A; Bode C; Staudacher DL; Wengenmayer T
Trials; 2020 Jun; 21(1):470. PubMed ID: 32493514
[TBL] [Abstract][Full Text] [Related]
14. Nebulised heparin for patients with or at risk of acute respiratory distress syndrome: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial.
Dixon B; Smith RJ; Campbell DJ; Moran JL; Doig GS; Rechnitzer T; MacIsaac CM; Simpson N; van Haren FMP; Ghosh AN; Gupta S; Broadfield EJC; Crozier TME; French C; Santamaria JD;
Lancet Respir Med; 2021 Apr; 9(4):360-372. PubMed ID: 33493448
[TBL] [Abstract][Full Text] [Related]
15. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Vilobelimab (IFX-1), a Novel Monoclonal Anti-C5a Antibody, in Patients With Early Severe Sepsis or Septic Shock-A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase IIa Trial (SCIENS Study).
Bauer M; Weyland A; Marx G; Bloos F; Weber S; Weiler N; Kluge S; Diers A; Simon TP; Lautenschläger I; Gründling M; Jaschinski U; Simon P; Nierhaus A; Moerer O; Reill L; Jörres A; Guo R; Loeffler M; Reinhart K; Riedemann N
Crit Care Explor; 2021 Nov; 3(11):e0577. PubMed ID: 34806021
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial.
Gao L; Li Y; He P; Chen Z; Yang H; Li F; Zhang S; Wang D; Wang G; Yang S; Gong L; Ding F; Ling M; Wang X; Ci L; Dai L; Gao GF; Huang T; Hu Z; Ying Z; Sun J; Zuo X
Lancet Child Adolesc Health; 2023 Apr; 7(4):269-279. PubMed ID: 36803632
[TBL] [Abstract][Full Text] [Related]
19. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial.
Lescure FX; Honda H; Fowler RA; Lazar JS; Shi G; Wung P; Patel N; Hagino O;
Lancet Respir Med; 2021 May; 9(5):522-532. PubMed ID: 33676590
[TBL] [Abstract][Full Text] [Related]
20. Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial.
Aman J; Duijvelaar E; Botros L; Kianzad A; Schippers JR; Smeele PJ; Azhang S; Bartelink IH; Bayoumy AA; Bet PM; Boersma W; Bonta PI; Boomars KAT; Bos LDJ; van Bragt JJMH; Braunstahl GJ; Celant LR; Eger KAB; Geelhoed JJM; van Glabbeek YLE; Grotjohan HP; Hagens LA; Happe CM; Hazes BD; Heunks LMA; van den Heuvel M; Hoefsloot W; Hoek RJA; Hoekstra R; Hofstee HMA; Juffermans NP; Kemper EM; Kos R; Kunst PWA; Lammers A; van der Lee I; van der Lee EL; Maitland-van der Zee AH; Mau Asam PFM; Mieras A; Muller M; Neefjes ECW; Nossent EJ; Oswald LMA; Overbeek MJ; Pamplona CC; Paternotte N; Pronk N; de Raaf MA; van Raaij BFM; Reijrink M; Schultz MJ; Serpa Neto A; Slob EMA; Smeenk FWJM; Smit MR; Smits AJ; Stalenhoef JE; Tuinman PR; Vanhove ALEM; Wessels JN; van Wezenbeek JCC; Vonk Noordegraaf A; de Man FS; Bogaard HJ
Lancet Respir Med; 2021 Sep; 9(9):957-968. PubMed ID: 34147142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
